India, June 3 -- Shares of Mineralys Therapeutics, Inc. (MLYS) declined after the company announced a royalty buyout transaction alongside significant new debt and equity financing.
The stock is currently trading at $24.79, down $4.07 or 14.09%, on the Nasdaq. It opened at $26.48 after closing the previous session at $28.85. The stock has traded between $12.59 and $47.65 over the past 52 weeks.
Mineralys agreed to repurchase all future royalty obligations related to lorundrostat from Tanabe Pharma Corporation for $200 million upfront and up to $100 million in future commercial milestone payments.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....